Global Dermatology CRO Market by Service (Clinical Monitoring, Regulatory/Medical Affairs), by Type (Clinical, Preclinical, Drug Discovery) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
Summary of the Report
Global dermatology CRO market was valued at USD 4.14 Billion in 2020. It is projected to grow at a compound annual rate (CAGR of 6.9%) between 2021 and 2028. This market is driven by the demand for topical dermatological medications such as anti-infective and anti-inflammatory, local anesthetics. emollients and cleansers to cure acne. The growing awareness of skin conditions, the need for quick diagnosis, and the rise in skin cancer and other skin diseases is driving the CRO (dermatological contract research organization) market. In 2020, the COVID-19 pandemic impacted the economy and continues to impact a wide range of businesses worldwide. The pandemic had little impact on the market for dermatology CRO. Virtual clinical trials were introduced and government measures to ensure that healthcare supply chains are intact. The ongoing vaccination programs and removal of shelter-in place regulations have helped to reduce the blockage in clinical trial. The market looks brighter as a result.
Market growth is expected to be boosted by the rising incidence of skin conditions around the world. According to the American Academy of Dermatology Association (AAD), acne is the most common skin condition in the United States, with 50 million Americans suffering from it every year. One in ten people will experience atopic dermatitis at some time in their lifetime. Around 7.5 million Americans suffer from psoriasis. Rosacea, a common skin condition, affects 16 millions people in the U.S. Each day, more then 9,500 people are diagnosed with skin cancer in the U.S.
Virtual trials, the use of technology and software solutions have been highlighted by the COVID-19 pandemic. The future dermatology CRO environment will be transformed by machine learning-based platforms, Artificial Intelligence and innovative trial designs. Biopharmaceutical investments in new and innovative therapies such as and regenerative medicine and drug development services are driving R&D. Sponsors are still seeking experts and services in many therapeutic areas.
Type Insights
With a revenue share exceeding 75.0%, the clinical segment was the dominant market for dermatology contract research organisations in 2020. This segment is growing due to an increasing number of biologics and the need for personalized medicine and orphan drugs as well as the demand for new technologies. Technology advancements, globalization in clinical trials and the increasing need for dermatology clinical trials to be conducted by CROs are some of the factors expected to fuel this growth.
Outsourcing phase III clinical trials to dermatology CROs was a smart move for the clinical segment. They are the most costly stage of a clinical trial and have helped to increase the revenue share of the segment in 2020. Preclinical will grow at 8.5% CAGR over the forecast period. Market expansion is likely due to the increasing number of preclinical trials that involve large molecules and the need to lower R&D costs.
Service Insights
The largest revenue share, more than 20% in 2020, was attributed to clinical monitoring. It is expected that it will continue its dominance during the forecast period. This could be because of an increase in clinical trials and the need for monitoring those trials, which are driving up the demand for services.
For a variety reasons, dermatology clinical research was outsourced to CROs over the past decade. These include cost-effectiveness and technical expertise. Smart analytics and real-time data collection technologies are expected to increase clinical monitoring data. Real-time data collection about medication safety and toxicities allows for prompt corrections such as trial re-designs or terminations. This will help propel the segment's growth.
Phase Insights
The market's top segment, phase III, dominated 2020 with a revenue share exceeding 50.0%. This is because phase III clinical trials are the most expensive and involve large numbers of participants. The median cost for a single-phase III clinical trial is approximately USD 19.0 million, with 59 new therapeutic medicines approved by FDA between 2015-16.
Phase III requires a greater number of patients and a longer treatment period. In 2020, the largest revenue share was held by phase II. The research can be divided into two parts. The first part involves looking at different doses and efficacy trials. The second half is about deciding on a dose.
Regional Insights
Asia Pacific was the dominant market in 2020 with a revenue share exceeding 40.0%. This market is expected to continue growing rapidly over the next few years. The high prevalence of chronic diseases, availability of diverse populations, ease with which patients can be recruited and retained and acceptance of laws are some of the reasons for this dominance. Market expansion is also being supported by government initiatives. In February 2018, the Central Drugs Standard Control Organization issued new rules that will cut down on the time required to get approval.
The largest number of dermatology trials in North America, as well as the outsourced work in this area, has resulted in a substantial revenue share for North American CROs. This market is also growing due to the government's increasing support of R&D activities via grants and money to research institutions and corporations. In 2018, the U.S. spent USD 194.2 billion on health and medical research and development.
Market Share Insights & Key Companies
As large CROs undergo inorganic growth, this market is consolidating. Icon plc, for example, entered into a definitive agreement in February 2021 to acquire PRA Health Sciences, which is valued at approximately USD 12 billion. Customers will benefit from the combined business due to its increased geographical, functional, therapeutic, and therapeutic reach. In 2021, Thermo Fisher entered into a definitive agreement with PPD to purchase the company for USD 17.4 million. The acquisition will allow Thermo Fisher to significantly increase its presence in the clinical research services market, particularly in the early phases of clinical trials. Healthcare contract researchers work to expand their services and improve their offerings. Parexel, for example, increased its relationship to the Society for Clinical Research Sites in October 2019. This is the only global organization that is solely dedicated protecting the interests clinical research sites. Parexel was a Site Engagement Partner and launched several initiatives to improve the patient experience during clinical trials. The following are some of the most prominent players in global dermatology CRO markets:
-
IQVIA HOLDINGS, INC.
-
Covance Inc.
-
Pharmaceutical Product Development, LLC (PPD).
-
Parexel International Corporation
-
Charles River Laboratories International, Inc.
-
Plc, Icon
-
Medidata Solutions, Inc.
-
Syneos Health
-
Pharmaron
-
GVK Biosciences Private Limited
-
Wuxi AppTec
-
MEDPACE HOLDINGS INC.
-
PRA Health Sciences
-
CTI Clinical Trial & Consulting
-
Bioskin
-
Proinnovera
-
Biorasi
-
Javara
-
TFS
Up Market Research published a new report titled “Dermatology CRO Market research report which is segmented by Service (Clinical Monitoring, Regulatory/Medical Affairs), by Type (Clinical, Preclinical, Drug Discovery), By Players/Companies Wuxi AppTec, Bioskin, MEDPACE HOLDINGS INC, Charles River Laboratories International Inc, Proinnovera, Syneos Health, Parexel International Corporation, IQVIA HOLDINGS INC, Pharmaceutical Product Development LLC (PPD), PRA Health Sciences, Medidata Solutions Inc, TFS, GVK Biosciences Private Limited, CTI Clinical Trial & Consulting, Icon Plc, Pharmaron, Javara, Covance Inc, Biorasi”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
Report Scope
Report Attributes | Report Details |
Report Title | Dermatology CRO Market Research Report |
By Service | Clinical Monitoring, Regulatory/Medical Affairs |
By Type | Clinical, Preclinical, Drug Discovery |
By Companies | Wuxi AppTec, Bioskin, MEDPACE HOLDINGS INC, Charles River Laboratories International Inc, Proinnovera, Syneos Health, Parexel International Corporation, IQVIA HOLDINGS INC, Pharmaceutical Product Development LLC (PPD), PRA Health Sciences, Medidata Solutions Inc, TFS, GVK Biosciences Private Limited, CTI Clinical Trial & Consulting, Icon Plc, Pharmaron, Javara, Covance Inc, Biorasi |
Regions Covered | North America, Europe, APAC, Latin America, MEA |
Base Year | 2020 |
Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
Forecast Year | 2028 |
Number of Pages | 227 |
Number of Tables & Figures | 159 |
Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global Dermatology CRO Market Report Segments:
The market is segmented by Service (Clinical Monitoring, Regulatory/Medical Affairs), by Type (Clinical, Preclinical, Drug Discovery).
Dermatology CRO Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Dermatology CRO Market
Overview of the regional outlook of the Dermatology CRO Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The Dermatology CRO Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of Dermatology CRO Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
1. Clinical Monitoring
2. Regulatory/Medical Affairs
7. By Type:1. Clinical
2. Preclinical
3. Drug Discovery
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Dermatology CRO Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the Dermatology CRO Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Dermatology CRO Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Dermatology CRO Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Dermatology CRO Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Dermatology CRO Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Dermatology CRO Market Size & Forecast, 2018-2028
4.5.1 Dermatology CRO Market Size and Y-o-Y Growth
4.5.2 Dermatology CRO Market Absolute $ Opportunity
Chapter 5 Global Dermatology CRO Market Analysis and Forecast by Service
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Service
5.1.2 Basis Point Share (BPS) Analysis by Service
5.1.3 Absolute $ Opportunity Assessment by Service
5.2 Dermatology CRO Market Size Forecast by Service
5.2.1 Clinical Monitoring
5.2.2 Regulatory/Medical Affairs
5.3 Market Attractiveness Analysis by Service
Chapter 6 Global Dermatology CRO Market Analysis and Forecast by Type
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Type
6.1.2 Basis Point Share (BPS) Analysis by Type
6.1.3 Absolute $ Opportunity Assessment by Type
6.2 Dermatology CRO Market Size Forecast by Type
6.2.1 Clinical
6.2.2 Preclinical
6.2.3 Drug Discovery
6.3 Market Attractiveness Analysis by Type
Chapter 7 Global Dermatology CRO Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Dermatology CRO Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Dermatology CRO Analysis and Forecast
9.1 Introduction
9.2 North America Dermatology CRO Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Dermatology CRO Market Size Forecast by Service
9.6.1 Clinical Monitoring
9.6.2 Regulatory/Medical Affairs
9.7 Basis Point Share (BPS) Analysis by Service
9.8 Absolute $ Opportunity Assessment by Service
9.9 Market Attractiveness Analysis by Service
9.10 North America Dermatology CRO Market Size Forecast by Type
9.10.1 Clinical
9.10.2 Preclinical
9.10.3 Drug Discovery
9.11 Basis Point Share (BPS) Analysis by Type
9.12 Absolute $ Opportunity Assessment by Type
9.13 Market Attractiveness Analysis by Type
Chapter 10 Europe Dermatology CRO Analysis and Forecast
10.1 Introduction
10.2 Europe Dermatology CRO Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Dermatology CRO Market Size Forecast by Service
10.6.1 Clinical Monitoring
10.6.2 Regulatory/Medical Affairs
10.7 Basis Point Share (BPS) Analysis by Service
10.8 Absolute $ Opportunity Assessment by Service
10.9 Market Attractiveness Analysis by Service
10.10 Europe Dermatology CRO Market Size Forecast by Type
10.10.1 Clinical
10.10.2 Preclinical
10.10.3 Drug Discovery
10.11 Basis Point Share (BPS) Analysis by Type
10.12 Absolute $ Opportunity Assessment by Type
10.13 Market Attractiveness Analysis by Type
Chapter 11 Asia Pacific Dermatology CRO Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Dermatology CRO Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Dermatology CRO Market Size Forecast by Service
11.6.1 Clinical Monitoring
11.6.2 Regulatory/Medical Affairs
11.7 Basis Point Share (BPS) Analysis by Service
11.8 Absolute $ Opportunity Assessment by Service
11.9 Market Attractiveness Analysis by Service
11.10 Asia Pacific Dermatology CRO Market Size Forecast by Type
11.10.1 Clinical
11.10.2 Preclinical
11.10.3 Drug Discovery
11.11 Basis Point Share (BPS) Analysis by Type
11.12 Absolute $ Opportunity Assessment by Type
11.13 Market Attractiveness Analysis by Type
Chapter 12 Latin America Dermatology CRO Analysis and Forecast
12.1 Introduction
12.2 Latin America Dermatology CRO Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Dermatology CRO Market Size Forecast by Service
12.6.1 Clinical Monitoring
12.6.2 Regulatory/Medical Affairs
12.7 Basis Point Share (BPS) Analysis by Service
12.8 Absolute $ Opportunity Assessment by Service
12.9 Market Attractiveness Analysis by Service
12.10 Latin America Dermatology CRO Market Size Forecast by Type
12.10.1 Clinical
12.10.2 Preclinical
12.10.3 Drug Discovery
12.11 Basis Point Share (BPS) Analysis by Type
12.12 Absolute $ Opportunity Assessment by Type
12.13 Market Attractiveness Analysis by Type
Chapter 13 Middle East & Africa (MEA) Dermatology CRO Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Dermatology CRO Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Dermatology CRO Market Size Forecast by Service
13.6.1 Clinical Monitoring
13.6.2 Regulatory/Medical Affairs
13.7 Basis Point Share (BPS) Analysis by Service
13.8 Absolute $ Opportunity Assessment by Service
13.9 Market Attractiveness Analysis by Service
13.10 Middle East & Africa (MEA) Dermatology CRO Market Size Forecast by Type
13.10.1 Clinical
13.10.2 Preclinical
13.10.3 Drug Discovery
13.11 Basis Point Share (BPS) Analysis by Type
13.12 Absolute $ Opportunity Assessment by Type
13.13 Market Attractiveness Analysis by Type
Chapter 14 Competition Landscape
14.1 Dermatology CRO Market: Competitive Dashboard
14.2 Global Dermatology CRO Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Wuxi AppTec
14.3.2 Bioskin
14.3.3 MEDPACE HOLDINGS INC
14.3.4 Charles River Laboratories International Inc
14.3.5 Proinnovera
14.3.6 Syneos Health
14.3.7 Parexel International Corporation
14.3.8 IQVIA HOLDINGS INC
14.3.9 Pharmaceutical Product Development LLC (PPD)
14.3.10 PRA Health Sciences
14.3.11 Medidata Solutions Inc
14.3.12 TFS
14.3.13 GVK Biosciences Private Limited
14.3.14 CTI Clinical Trial & Consulting
14.3.15 Icon Plc
14.3.16 Pharmaron
14.3.17 Javara
14.3.18 Covance Inc
14.3.19 Biorasi